TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4096357

Group type: EXPERIMENTAL
Intervention: TTS-scopolamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: TTS-placebo
Number of subjects: 40
Study: 31216086

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400/100 mg) once daily for 12 weeks
Number of subjects: 111
Study: 29693533

Group type: EXPERIMENTAL
Intervention: Therapist emails rated for adherence and quality
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ICBT-TRS ratings
Number of subjects: 91
Study: 27113490

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Overall genetic risk score (GRS)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Dietary fat interaction
Number of subjects: 733
Study: 24813819

Group type: EXPERIMENTAL
Intervention: Mailed access to FIT and colonoscopy
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Telephone navigation for FIT and colonoscopy
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Preference for FIT
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Preference for colonoscopy
Number of subjects: 945
Study: 24152757

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Number of subjects: 478
Study: 20636488

Group type: EXPERIMENTAL
Intervention: Tecnis Z9003(®) (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acrysof IQ SN60WF(®) (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Akreos ADAPT‐AO(®) (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 90
Study: 19056576

Group type: EXPERIMENTAL
Intervention: Capsinoids (6 mg/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17179252

Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (CobraPLA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)‐Classic
Number of subjects: 40
Study: 15559606

Group type: EXPERIMENTAL
Intervention: IFN‐beta 1‐a
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IFN‐beta 1‐b
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both preparations of IFN‐beta 1‐a
Number of subjects: 47

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 47
Study: 11521785

Group type: EXPERIMENTAL
Intervention: AC + EP (adriamycin + cyclophosphamide + etoposide + cisplatin)
Number of subjects: 162

Group type: COMPARATOR
Intervention: AC (adriamycin + cyclophosphamide)
Number of subjects: 162
Study: 9716578

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/d + Ticlopidine 500 mg/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7593999

Group type: EXPERIMENTAL
Intervention: Health promotion program with physical fitness and exercise components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2169780

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg (additional doses allowed)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Granisetron (both doses)
Number of subjects: 443
Study: 7021163

Group type: EXPERIMENTAL
Intervention: Bronchodilator aerosol with tube extension (terbutaline sulphate 0.25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ordinary aerosol
Number of subjects: 12
Study: 31029045

Group type: EXPERIMENTAL
Intervention: Higher cocoa chocolate (HCC; ∼90%; 20 g daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower cocoa chocolate (LCC; ∼55%; 20 g daily)
Number of subjects: 30
Study: 28652048

Group type: EXPERIMENTAL
Intervention: Active low-intensity vibration (LIV) device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo LIV device
Number of subjects: 30
Study: 26395498

Group type: EXPERIMENTAL
Intervention: Standard dressings
Number of subjects: 460

Group type: COMPARATOR
Intervention: Negative pressure wound therapy
Number of subjects: 460
Study: 23228972

Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol per day for 3 months
Number of subjects: 35
Study: 21492495

Group type: EXPERIMENTAL
Intervention: Solid food form (12.5% of energy need)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Beverage food form (12.5% of energy need)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sedentary (Sed)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Solid food form
Number of subjects: 34

Group type: COMPARATOR
Intervention: Beverage food form
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) and food form (FFNS)
Number of subjects: 34
Study: 19701512

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (irradiated)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (irradiated)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (irradiated)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Clearfil S3 Bond (nonirradiated)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Clearfil SE Bond (nonirradiated)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Prime & Bond NT (nonirradiated)
Number of subjects: 84
Study: 16814981

Group type: EXPERIMENTAL
Intervention: OCI-R subscales for OCD patients
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: OCI-R scores for patients acknowledging symptom subtype as present but not primary on the Y-BOCS
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: OCI-R subscales
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: OCI-R
Number of subjects: 203
Study: 14734063

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (25mg/ml) treatment for 5 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study: 11495669

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 18

Group type: COMPARATOR
Intervention: Males
Number of subjects: 18
Study: 9766795

Group type: EXPERIMENTAL
Intervention: Platelet von Willebrand factor (vWF) activity levels in HPS patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor (vWF) activity levels in HPS patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multimeric structure of plasma vWF in 11 HPS patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of platelet and plasma vWF values with bleeding histories
Number of subjects: 30
Study: 8153984

Group type: COMPARATOR
Intervention: IVER 100 (100 micrograms/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IVER 400 (400 micrograms/kg)
Number of subjects: 43
Study: 2111327

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 7212246

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 0
Study: 31318748

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (n = 32)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dry needling (n = 33)
Number of subjects: 65
Study: 28061321

Group type: EXPERIMENTAL
Intervention: Subcutaneous vitamin E ointment application (Group 1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No vitamin E ointment application (Group 2)
Number of subjects: 101
Study: 26001670

Group type: EXPERIMENTAL
Intervention: Integrative cognitive behavioral therapy for PGD (PG-CBT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (wait list)
Number of subjects: 51
Study: 24303144

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21129746

Group type: COMPARATOR
Intervention: Non-users of lipid-lowering treatment (LLT)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Fibrate users
Number of subjects: 1280
Study: 19413147

Group type: EXPERIMENTAL
Intervention: Baseline polysomnograms from all children
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Night 1 PLMS index
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Individual data for 15 children with 5 or more PLMS per hour
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PLMS indexes of children who were medication free for a third and fourth night (n = 7) or just a third night (n = 2)
Number of subjects: 36
Study: 17388751

Group type: EXPERIMENTAL
Intervention: Diskus (DK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Handihaler (HH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inhalation technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inhalation resistance
Number of subjects: 60
Study: 15220017

Group type: EXPERIMENTAL
Intervention: Diazepam (0.28 mg/kg IV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diazepam vehicle (alcohol and propylene glycol IV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 25
Study: 11231977

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen, 0.625 mg/day
Number of subjects: 25
Study: 9748117

Group type: EXPERIMENTAL
Intervention: 5FU dose adjusted according to the 5FU area under the curve (AUC0‐48h; PK‐arm)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard dose of 5FU (St‐arm; 4 g/m2)
Number of subjects: 122
Study: 8040918

Group type: EXPERIMENTAL
Intervention: Alcohol Skills Training Program (ASTP), a cognitive behavioral approach, details of dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 3555598

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31896568

Group type: EXPERIMENTAL
Intervention: 15-caliber coils
Number of subjects: 210

Group type: COMPARATOR
Intervention: 10-caliber coils (Control)
Number of subjects: 210
Study: 30243201

Group type: EXPERIMENTAL
Intervention: EM-guided nasoenteral feeding tube placement
Number of subjects: 161

Group type: COMPARATOR
Intervention: Endoscopic nasoenteral feeding tube placement
Number of subjects: 161
Study: 28318867

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 26205998

Group type: EXPERIMENTAL
Intervention: Lateral zoned insoles (2, 4, and 6mm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Medial zoned insoles (2, 4, and 6mm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control insoles (0mm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Impaired vision condition
Number of subjects: 15
Study: 23266280

Group type: EXPERIMENTAL
Intervention: Dietary planning intervention (leaflet on fruit consumption with a planning sheet)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 165
Study: 21378250

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study: 18180620

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg) + Propranolol (80 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16609087

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-negative tumors
Number of subjects: 6644

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-positive tumors
Number of subjects: 6644

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for ER-negative tumors
Number of subjects: 6644

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for ER-positive tumors
Number of subjects: 6644
Study: 12969165

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 26
Study: 10780142

Group type: EXPERIMENTAL
Intervention: Healthy child (HL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Child in remission from cancer and no longer undergoing treatment (RCL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Child in remission and still undergoing treatment (RCTL)
Number of subjects: 0
Study: 8627642

Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide‐methotrexate‐fluorouracil‐vincristine‐prednisone) for two 6‐week cycles or six 4‐week cycles, followed by VATH (vinblastine‐doxorubicin‐thiotepa‐fluoxymesterone)
Number of subjects: 280
Study: 1471706

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment for 6 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study: 6718766

Group type: EXPERIMENTAL
Intervention: Neurotensin infusion at 3 pmol X kg‐1 X min‐1 for 4 h
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Neurotensin infusion
Number of subjects: 6
Study: 30583082

Group type: EXPERIMENTAL
Intervention: 12,000 IU vitamin D3
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D3
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: 48,000 IU vitamin D3
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 379
Study: 30106621

Group type: EXPERIMENTAL
Intervention: Breakfast before exercise (BE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Overnight fasted exercise (FE)
Number of subjects: 12
Study: 26919080

Group type: EXPERIMENTAL
Intervention: Desensibilize Nano‐P paste (20% hydroxyapatite, potassium nitrate, and sodium fluoride; 9000 ppm fluoride)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Desensibilize Nano‐P associated with experimental home‐care pastes (10% HA, potassium nitrate, and sodium fluoride; 900 ppm fluoride)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pro‐Relief professional paste (8% arginine with Pro‐Argin technology) associated with home‐care toothpaste (8% arginine, sodium monofluorophosphate, 1450 ppm fluoride)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Duraphat professional varnish (NaF varnish, 22,600 ppm fluoride)
Number of subjects: 28
Study: 24041748

Group type: EXPERIMENTAL
Intervention: DrAFT‐CS
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: DrAFT‐CS+
Number of subjects: 176

Group type: COMPARATOR
Intervention: Moderation skills only (MSO)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 176
Study: 23096033

Group type: EXPERIMENTAL
Intervention: Cytoflavin (2 tablets twice a day) and standard therapy (acetylsalicylic acid and antihypertensive drugs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (acetylsalicylic acid and antihypertensive drugs)
Number of subjects: 60
Study: 20666654

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vitamins C and E (VCE)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise plus Vitamins C and E (EX + VCE)
Number of subjects: 32
Study: 17623754

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Inhaled budesonide (400 microg per day in two doses)
Number of subjects: 62
Study: 12124481

Group type: COMPARATOR
Intervention: AGAb bone marrow immunoscintigraphy (370 MBq of (99m)Tc labelled anti‐NCA‐95 antigranulocyte antibodies)
Number of subjects: 23

Group type: COMPARATOR
Intervention: AGAb bone marrow immunoscintigraphy
Number of subjects: 23
Study: 10214632

Group type: EXPERIMENTAL
Intervention: Coloured filters (Blue tints, Diagnosed tints)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Placebo tints
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no coloured filters)
Number of subjects: 148
Study: 7825764

Group type: EXPERIMENTAL
Intervention: Guideline recommendations for discharge by day 3
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Concurrent review classification
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Correct classification of patients
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Severity of illness measurement
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Physician compliance with guidelines
Number of subjects: 230
Study: 2114131

Group type: EXPERIMENTAL
Intervention: High referral general practitioners (n = 192)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Average referral general practitioners (n = 88)
Number of subjects: 280
Study: 385399

Group type: EXPERIMENTAL
Intervention: mianserin 30‐60 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: diazepam 15‐30 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 30707761

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 28383292

Group type: EXPERIMENTAL
Intervention: Peripheral nerve electrical stimulation (PNS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo PNS
Number of subjects: 32
Study: 25840004

Group type: EXPERIMENTAL
Intervention: Placebo group received an intranasal dose of 'serotonin' (placebo) prior to the second stress test.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study: 23827259

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (192 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-dose naltrexone (384 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 21470361

Group type: EXPERIMENTAL
Intervention: Single (30-min exercise)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repeated (three 10-min bouts of exercise)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 9
Study: 19788970

Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 302
Study: 17692720

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Varenicline 0.25 mg BID
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 mg BID
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Varenicline (all doses)
Number of subjects: 618
Study: 15122610

Group type: EXPERIMENTAL
Intervention: Curative resection (R0)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Lymph-node negative status
Number of subjects: 366

Group type: COMPARATOR
Intervention: Surgical exploration
Number of subjects: 366
Study: 11281235

Group type: EXPERIMENTAL
Intervention: Calcium-blocking drugs
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sequential monotherapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ACE inhibitors, calcium-blocking drugs, diuretics
Number of subjects: 74
Study: 9579506

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 453
Study: 7914958

Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 2649

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 2649
Study: 2645924

Group type: EXPERIMENTAL
Intervention: Protein-restricted diet
Number of subjects: 0
Study: 4907514

Group type: EXPERIMENTAL
Intervention: Ampicillin, 1 g. four times a day for 28 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo in identical capsules for 28 days
Number of subjects: 68
Study: 31179008

Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: GLPG1690 200 mg
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 28578139

Group type: EXPERIMENTAL
Intervention: Diabetes patients without peripheral neuropathy (DM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Patients with moderate/severe diabetic peripheral neuropathy (DPN)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-diabetic controls (Ctrl)
Number of subjects: 67
Study: 26009529

Group type: EXPERIMENTAL
Intervention: Brief physician training on predominantly non-verbal communication
Number of subjects: 16

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study: 23725973

Group type: EXPERIMENTAL
Intervention: L-carnitine-containing peritoneal dialysis solution (0.1%, 2 g/bag)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard glucose-based solution (1.5% or 2.5%)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: L-carnitine-containing solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard glucose-based solution
Number of subjects: 35
Study: 21740832

Group type: EXPERIMENTAL
Intervention: SEM‐rTMS
Number of subjects: 164

Group type: COMPARATOR
Intervention: C‐rTMS
Number of subjects: 164

Group type: COMPARATOR
Intervention: sham‐rTMS
Number of subjects: 164
Study: 19719939

Group type: EXPERIMENTAL
Intervention: BHR group (metal-on-metal femoral heads, average size 45 mm)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BHR group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional group (28-mm metal-on-polyethylene heads)
Number of subjects: 31
Study: 17615905

Group type: EXPERIMENTAL
Intervention: Zinc plus multivitamin syrup
Number of subjects: 154

Group type: COMPARATOR
Intervention: Multivitamin syrup
Number of subjects: 154
Study: 12926799

Group type: EXPERIMENTAL
Intervention: Beta-carotene (25 mg) twice daily for 36 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (saccharose capsules)
Number of subjects: 62